New drug combo shows promise for myeloma patients who Can't have transplant

NCT ID NCT03984097

Completed Disease control Sponsor: Takeda Source: ClinicalTrials.gov ↗

First seen Feb 20, 2026 · Last updated May 23, 2026 · Updated 12 times

Summary

This early-phase study tested the safety of adding TAK-079 to standard treatments for 50 adults newly diagnosed with multiple myeloma who were not eligible for stem cell transplant. The goal was to find the right dose and check for side effects. While the drug may help control the disease, patients will likely need ongoing therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Alabama Oncology

Birmingham, Alabama, 35211, United States
American Oncology Partners of Maryland, PA

Bethesda, Maryland, 20817, United States
Columbia University Medical Center

New York, New York, 10032, United States
Froedtert Hospital & the Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Good Samaritan Hospital

Cincinnati, Ohio, 45220, United States
Levine Cancer Institute

Charlotte, North Carolina, 28204, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Oregon Health & Science University

Portland, Oregon, 97239, United States
Pacific Cancer Care

Monterey, California, 93940, United States

Conditions

Explore the condition pages connected to this study.

MULTIPLE MYELOMA